Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
Equillium, Inc. (EQ)
Last equillium, inc. earnings: 3/26 04:07 pm
Check Earnings Report
Company Research
Source: Business Wire
20% of all subjects that completed the 24-week treatment period achieved SALT = 2029% of completed subjects with moderate to severe disease (baseline SALT 35 to EQ101 was well tolerated in subjects with alopecia areata with no serious adverse events reportedData supports advancing EQ101 development in alopecia areata to include dose and delivery optimizationData provides further support for opportunistic expansion in other dermatological conditions where IL-2, IL-9 and IL-15 inhibition is important such as vitiligo and atopic dermatitis LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline data from its Phase 2, single dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate, severe or very-severe alopecia areata (AA), an autoimmune disease driven by
Show less
Read more
Impact Snapshot
Event Time:
EQ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EQ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EQ alerts
High impacting Equillium, Inc. news events
Weekly update
A roundup of the hottest topics
EQ
News
- Equillium to be included in the Russell Microcap® Index [Yahoo! Finance]Yahoo! Finance
- Equillium to be included in the Russell Microcap® IndexBusiness Wire
- Equillium, Inc. (NASDAQ: EQ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata [Yahoo! Finance]Yahoo! Finance
EQ
Earnings
- 5/9/24 - Beat
EQ
Sec Filings
- 6/4/24 - Form 8-K
- 5/23/24 - Form 4
- 5/23/24 - Form 4
- EQ's page on the SEC website